Taiho Pharmaceutical and Cullinan Oncology Establish Collabora...
TOKYO and CAMBRIDGE, Massachusetts, Feb. 5, 2019 /Kyodo JBN-AsiaNet/-- -FIH Study in EGFR Exon 20 Insertions Will Commence in 2019- Taiho Pharmaceutical Co., Ltd. and Cullinan Oncology, LLC announced on February 5 an agreement to develop TAS6417, a novel EGFR (epidermal growth factor receptor) tyrosine kinase inh...
Authors: LATEST ASIANET NEWS RELEASES